Royce & Associates LP Sells 156,754 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Royce & Associates LP trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 7.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,864,351 shares of the biopharmaceutical company’s stock after selling 156,754 shares during the period. Royce & Associates LP’s holdings in Catalyst Pharmaceuticals were worth $38,909,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of Catalyst Pharmaceuticals by 9.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after purchasing an additional 33,888 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Catalyst Pharmaceuticals by 13.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock valued at $8,710,000 after acquiring an additional 50,888 shares in the last quarter. Wellington Management Group LLP purchased a new position in Catalyst Pharmaceuticals during the third quarter valued at $1,185,000. Redhawk Wealth Advisors Inc. purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $1,273,000. Finally, Spire Wealth Management grew its stake in Catalyst Pharmaceuticals by 1,342.9% during the fourth quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 13,429 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Analyst Ratings Changes

CPRX has been the subject of several research analyst reports. Robert W. Baird raised their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Stephens reaffirmed an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $32.50.

Catalyst Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ:CPRX opened at $21.02 on Friday. The firm has a fifty day simple moving average of $22.26 and a two-hundred day simple moving average of $21.53. The stock has a market capitalization of $2.55 billion, a P/E ratio of 17.81, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $24.64.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.